Skip to main content

Table 2 Estimated annual dilatation rates over a mean follow-up of 3.4 years

From: A prospective, randomized, placebo-controlled, double-blind, multicenter study of the effects of irbesartan on aortic dilatation in Marfan syndrome (AIMS trial): study protocol

Number of patients in placebo group

Number of patients in irbesartan group

Annual growth on placebo (mm)

Annual growth on irbesartan (mm)

SD of annual growth (mm)

142

142

1

0.4

1.8

169

169

1

0.45

1.8

204

204

1

0.5

1.8

252

252

1

0.55

1.8

318

318

1

0.6

1.8